Does Cabergoline Shrink Man Boobs?

Cabergoline and gynaecomastia are closely linked when raised prolactin is the underlying cause of breast tissue enlargement in men. Cabergoline is a dopamine agonist licensed in the UK for hyperprolactinaemia, and by lowering prolactin it can help reverse the hormonal imbalance that drives glandular breast growth. However, it is not a direct treatment for gynaecomastia from other causes, and its use requires proper clinical assessment. This article explains how high prolactin leads to breast tissue growth, what the evidence shows, what side effects to expect, and when to see a GP.

Can cabergoline reduce gynaecomastia in men?

Cabergoline can reduce gynaecomastia in men when elevated prolactin is the cause, as it lowers prolactin levels and addresses the hormonal trigger for breast tissue growth, but it is not effective for gynaecomastia from other causes.

Cabergoline can reduce gynaecomastia (sometimes informally called 'man boobs') in men when the underlying cause is elevated prolactin, a condition known as hyperprolactinaemia. Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, and when it is driven by excess prolactin, treating that hormonal imbalance is the logical first step. Cabergoline is a dopamine agonist licensed in the UK by the MHRA for the treatment of hyperprolactinaemia and prolactin-secreting pituitary tumours (prolactinomas).^[1][2] By lowering prolactin levels, it can address one of the hormonal triggers that leads to breast tissue growth.

It is important to understand that cabergoline is not a direct treatment for gynaecomastia itself. Its effectiveness depends entirely on whether raised prolactin is the cause. Gynaecomastia has many other causes, including puberty, obesity, certain medications, liver disease and other hormonal imbalances, and in those cases cabergoline would not be expected to help. A thorough clinical assessment is therefore essential before any treatment is considered.

Cabergoline is a prescription-only medicine in the UK and should only be taken under medical supervision following appropriate investigation. Men who suspect they have gynaecomastia or high prolactin should seek a GP assessment rather than attempting to self-medicate. Bolt Pharmacy is a GPhC-registered online pharmacy (GPhC regulates pharmacy premises in Great Britain) offering online consultations with prescriber review and pharmacist support; cabergoline is only one option a prescriber may consider after a consultation, and is prescribed only where clinically appropriate.

Why high prolactin levels can cause breast tissue growth in men

High prolactin suppresses GnRH, reducing testosterone production and allowing oestrogen to stimulate glandular breast tissue growth, leading to gynaecomastia in men.

High prolactin levels cause breast tissue growth in men by disrupting the normal balance between oestrogen and testosterone. Prolactin is a hormone produced by the pituitary gland, primarily associated with milk production in women. In men, it is present at low levels and plays a role in reproductive health. When prolactin rises significantly, it suppresses the production of gonadotrophin-releasing hormone (GnRH), which in turn reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH). This cascade leads to lower testosterone production by the testes.

With testosterone levels falling and the relative influence of oestrogen increasing, the hormonal environment in men begins to resemble that which promotes breast tissue development. Oestrogen stimulates the growth of glandular breast tissue, and without adequate testosterone to counterbalance it, gynaecomastia can develop. In some cases, men with hyperprolactinaemia may also experience galactorrhoea, which is the inappropriate production of milk from the nipple, though this is less common than in women.

The most frequent causes of pathologically elevated prolactin in men include prolactinomas (benign pituitary tumours), certain medications, hypothyroidism and chronic kidney disease. Medicines commonly associated with raised prolactin include antipsychotics (such as risperidone and haloperidol), metoclopramide, domperidone, some antidepressants, verapamil and opioids.^[3] This list is not exhaustive, and men should not stop or change any prescribed medicine, particularly antipsychotics, without first speaking to their prescriber. Stress and vigorous exercise can cause transient rises in prolactin, but these are rarely clinically significant.

It is also worth noting that laboratory results can occasionally be affected by macroprolactin, a form of prolactin that is less biologically active but can cause a falsely elevated reading.^[6] Specialist input is advisable when interpreting prolactin results, particularly if symptoms do not fit the clinical picture.

What does the evidence say about cabergoline and gynaecomastia?

Evidence supports cabergoline for normalising prolactin and shrinking prolactinomas, with breast tissue regression as a secondary benefit, but direct evidence on gynaecomastia as a primary outcome remains limited.

The evidence supports cabergoline as an effective treatment for hyperprolactinaemia, and in cases where gynaecomastia is directly caused by elevated prolactin, normalising prolactin levels can lead to regression of breast tissue. Clinical guidance, including that from the Pituitary Foundation and the Endocrine Society, indicates that cabergoline is generally more effective and better tolerated than the older dopamine agonist bromocriptine for reducing prolactin levels and shrinking prolactinomas.^[6][16]

However, the direct evidence specifically examining cabergoline's effect on gynaecomastia as a primary outcome is limited. Most available data comes from studies focused on prolactin normalisation and tumour reduction, with breast tissue changes reported as secondary findings. The degree to which gynaecomastia resolves depends on how long it has been present. Longstanding gynaecomastia may involve fibrotic changes to the glandular tissue that are less likely to reverse with hormonal treatment alone, regardless of how well prolactin is controlled.^[19]

In men whose gynaecomastia is not caused by hyperprolactinaemia, there is no credible evidence that cabergoline provides any benefit. Using cabergoline outside its licensed indication is not routine practice and should only be considered under specialist guidance with a clear clinical rationale, in line with UK prescribing norms for off-label medicines. For men with drug-induced gynaecomastia, the first step recommended in clinical practice is to review and, where possible, discontinue the causative medication in discussion with the prescriber. Under specialist care, medicines such as tamoxifen are sometimes used off-label for painful or persistent gynaecomastia, though this is not a standard first-line approach.^[17][18] Surgical options such as subcutaneous mastectomy may be considered for persistent or fibrotic gynaecomastia that does not respond to medical management, and referral to a specialist endocrinologist or surgeon may be appropriate in such cases.

Side effects and safety considerations for men taking cabergoline

Cabergoline commonly causes nausea, headache and dizziness, and carries serious risks including cardiac valvulopathy, fibrotic reactions and impulse control disorders, requiring baseline echocardiography and ongoing monitoring.

Cabergoline carries a range of side effects that men should be aware of before starting treatment. The most commonly reported adverse effects include nausea, headache, dizziness and fatigue, particularly when treatment is first initiated. These effects are often dose-dependent and can be minimised by starting at a low dose and taking the tablet with food. Less commonly, cabergoline can cause postural hypotension, which means a drop in blood pressure on standing, so men should be cautious when rising quickly from a seated or lying position. Men who experience dizziness or somnolence should avoid driving or operating machinery until they know how the medicine affects them.

Of particular clinical importance is the association between cabergoline and cardiac valvulopathy, specifically thickening or leakage of the heart valves. The UK SmPC and MHRA Drug Safety Update advise that a baseline echocardiogram should be performed before starting cabergoline, and that periodic echocardiographic monitoring should continue during long-term treatment.^[1][2] Pre-existing valvular heart disease is a contraindication to cabergoline, and men should inform their prescriber of any history of heart disease before starting treatment.^[1][2]

As an ergot-derived medicine, cabergoline also carries a risk of fibrotic reactions, which can affect the lungs, heart lining (pericardium) or the tissue behind the abdomen (retroperitoneum).^[1][2] Men should seek prompt medical review if they develop unexplained breathlessness, a persistent cough, chest pain, back or flank pain, or swelling that cannot be explained. These symptoms should not be ignored.

Cabergoline has also been associated with impulse control disorders, including compulsive gambling, hypersexuality and binge eating, in a small number of patients.^[5][12] Men and their families should be counselled about these risks at the outset, and any changes in behaviour should be reported to the prescriber promptly. Men with a history of psychosis or significant psychiatric illness should discuss this with their prescriber before starting cabergoline, as dopamine agonists can exacerbate psychiatric symptoms.

Cabergoline is contraindicated in individuals with known hypersensitivity to the medicine or to ergot alkaloids, and in those with pre-existing valvular heart disease. Regarding pregnancy, the UK SmPC advises that cabergoline should generally be avoided and discontinued once pregnancy is confirmed; continuation may only be considered under specialist supervision where the benefit clearly outweighs the risk. Men should not stop or adjust their dose without first speaking to their prescriber. Suspected adverse reactions to cabergoline should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

When should you see a GP about gynaecomastia or high prolactin?

Men should see a GP promptly if they notice persistent breast enlargement, nipple discharge or a hard irregular lump, as these require investigation to exclude serious causes including male breast cancer.

Men should see their GP if they notice persistent or progressive breast tissue enlargement, breast tenderness, nipple discharge, or any lump in the breast area that does not resolve within a few weeks. While gynaecomastia is usually benign, male breast cancer, though rare, must be excluded. Red flags that warrant prompt assessment include a hard, irregular or one-sided lump, nipple retraction or bleeding, skin dimpling or puckering, and swollen lymph nodes in the armpit. A GP can arrange initial blood tests to measure prolactin, testosterone, oestrogen, thyroid function and liver enzymes, which help to identify the underlying cause.

If blood tests reveal significantly elevated prolactin, a GP will typically refer to an endocrinologist for further assessment, which may include MRI imaging of the pituitary gland to look for a prolactinoma.^[6] NICE CKS guidance on gynaecomastia and on galactorrhoea and hyperprolactinaemia supports a structured approach to investigation and referral, and men should not attempt to self-diagnose or self-treat based on symptoms alone. Cabergoline is a prescription-only medicine and requires proper clinical assessment before it is initiated. Men should also not stop or change any medicine they are currently prescribed, including antipsychotics or other medicines that may be contributing to raised prolactin, without first discussing this with their prescriber.

For sudden severe headache, visual disturbances or significant collapse, men should call 999 or go immediately to the nearest accident and emergency department, as these symptoms could indicate pituitary apoplexy, which is a medical emergency. Men taking cabergoline who experience less acute but concerning symptoms, such as new dizziness or unexpected side effects, should contact NHS 111 for urgent advice. Routine follow-up with a GP or specialist is important for anyone on long-term cabergoline therapy to monitor prolactin levels, assess treatment response and check for any emerging side effects, including those affecting the heart.

Frequently Asked Questions